Acera Surgical - Pioneer in Synthetic Electrospun Biomaterials for Regenerative Wound Care

Company Overview (Updated April 2026)

Acera Surgical is a bioScience company and leader in electrospun technology innovation for regenerative medicine, headquartered in St. Louis, Missouri, USA. Founded in 2013 as a spin-out from Washington University in St. Louis, the company develops and commercializes fully synthetic electrospun fiber matrices that mimic native human extracellular architecture to support soft tissue healing and reinforcement across surgical applications.

Corporate Status (Post-Acquisition):

- Parent Company: Solventum Corporation (NYSE: SOLV) - completed acquisition December 23, 2025

- Former Status: Privately held bioscience company (2013-2025)

- Headquarters: St. Louis, Missouri, USA

- Founded: 2013

- Industry: Regenerative Medicine / Advanced Wound Care / Medical Devices

Historical Evolution:

- 2013: Founded as Washington University spin-out by Dr. Matthew MacEwan and team; originated from Olin Cup competition winner NanoMed project

- June 2016: Raised $4 million Seed Round

- October 2018: Completed Series A financing

- April 2020: Secured PPP debt financing

- 2023: FDA clearance for Restrata MiniMatrix powder configuration

- June 2025: Received expanded FDA 510(k) clearance for soft tissue reinforcement indication

- November 2025: Announced definitive agreement to be acquired by Solventum

- December 23, 2025: Completed acquisition by Solventum

Acquisition by Solventum (December 2025)

Transaction Details

Deal Structure:

- Upfront Payment: $725 million in cash

- Contingent Payments: Up to $125 million based on achievement of certain future milestones

- Total Deal Value: Up to $850 million

- Closing Date: December 23, 2025

- Funding: Solventum used cash on hand; no additional debt incurred

Strategic Rationale:

- Expands Solventum's MedSurg portfolio into fast-growing synthetic tissue matrices technology space

- Addresses the $900 million regenerative tissue matrices market within U.S. acute care settings

- Complements Solventum's existing advanced wound care portfolio and negative pressure wound therapy (NPWT) leadership

Financial Impact:

- Expected to be slightly dilutive to adjusted EPS in 2026

- Expected to be accretive to adjusted EPS beginning in 2027

- Acera generated approximately $90 million in sales in 2025

Technology Platform & Product Portfolio

Proprietary Electrospinning Technology

Core Technology:

- Proprietary electrospinning platform creates fully synthetic, fully resorbAble electrospun fiber matrices

- Mimics native human extracellular matrix (ECM) architecture

- Uses bioresorbable synthetic polymers with well-established safety profiles

- Matrix provides structural support during critical healing phase (3-4 weeks resorption time)

- No animal or human components; eliminates risk of disease transmission or rejection

Restrata® Product Line

Restrata Sheet:

- Fully synthetic, fully resorbable electrospun matrix in sheet form

- FDA 510(k) cleared for wound healing and soft tissue reinforcement

Restrata Meshed:

- Meshed configuration for expanded coverage and conformability

- FDA 510(k) cleared for wound healing and soft tissue reinforcement

Restrata MiniMatrix (FDA Cleared 2023):

- Powder/mini-matrix configuration for diverse clinical applications

- Extensive clinical data in diabetic foot ulcer applications

- Designed for challenging wound geometries and hard-to-treat areas

Clinical Applications:

- Diabetic foot ulcers, pressure ulcers, trauma wounds

- Surgical incisions at risk of dehiscence

- Soft tissue reinforcement beneath primary skin closures in plastic and reconstructive procedures

Clinical & Regulatory Milestones

FDA 510(k) Clearances

June 2025 Expanded Clearance:

- New indication for soft tissue reinforcement applications

- Allows implantation to reinforce soft tissue where weakness exists

- Addresses surgical site dehiscence and wound breakdown challenges

- Positions Restrata for expansion into orthopedic and reconstructive surgery specialties

Financial History & Investors

Funding Rounds (Pre-Acquisition)

Total Raised: Approximately $10.9 million

- Seed Round (June 2016): $4 million

- Series A (October 2018): Completed

- PPP Loan (April 2020): Debt financing

Key Investors:

- MBX Capital, Missouri Technology Corporation, St. Louis Arch Angels, Washington University Skandalaris Center

Leadership Team

Executive Management

Chief Executive Officer: Mike Finegan - Led company through FDA clearances and Solventum acquisition

Co-Founder & Chief Scientific Officer: Dr. Matthew MacEwan, MD, PhD - Washington University alumnus; co-inventor of electrospinning technology platform; winner of Skandalaris Center's Olin Cup competition

Market Context & Competitive Landscape

Market Position

Addressable Market:

- Synthetic tissue matrices category within acute care settings: ~$900 million (U.S. market)

- Broader advanced wound care market growing at 4.79% CAGR

Key Competitors:

- Integra LifeSciences (primary competitor in inpatient segment)

- Nurami (Israel-based competitor)

Competitive Differentiation:

- Fully synthetic, fully resorbable (no animal/human components)

- Proprietary electrospinning technology mimics native ECM

- Dual indication (wound healing + soft tissue reinforcement) with one product platform

- 3-4 week resorption profile optimized for acute healing phase

- Made in the United States

Strategic Outlook (2026 Onward)

Post-Acquisition Integration

- Integration into Solventum's MedSurg business unit

- Leveraging Solventum's global commercial platform and specialized wound care sales force

- Solventum 2026 guidance: Organic sales growth +2.0% to +3.0%; adjusted EPS $6.40-$6.60

- Expanding into new surgical specialties via soft tissue reinforcement indication

Contact Information

Headquarters

Address: Acera Surgical, St. Louis, Missouri, USA
   Website: www.acera-surgical.com

Parent Company (Post-December 2025)

Solventum Corporation (NYSE: SOLV)
   Headquarters: St. Paul, Minnesota, USA
   Website: www.solventum.com

Keywords: Acera Surgical, Restrata, Restrata MiniMatrix, Restrata Sheet, Restrata Meshed, electrospinning, synthetic biomaterials, regenerative wound care, soft tissue reinforcement, Solventum, Solventum acquisition, Mike Finegan, Matthew MacEwan, St. Louis, Missouri, Washington University, FDA 510k, 2025 acquisition, $850 million, Olin Cup